Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy

• Verfasst von: Frühauf, Stefan [VerfasserIn]
• Verfasst von: Schmitt, Karin [VerfasserIn]
• Verfasst von: Veldwijk, Marlon R. [VerfasserIn]
• Verfasst von: Topaly, Julian [VerfasserIn]
• Verfasst von: Benner, Axel [VerfasserIn]
• Verfasst von: Zeller, W. Jens [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Haas, Rainer [VerfasserIn]
• Titel: Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy
• Titelzusatz: an update on 100 patients
• Verf.angabe: Stefan Fruehauf, Karin Schmitt, Marlon R. Veldwijk, Julian Topaly, Axel Benner, W. Jens Zeller, Anthony D. Ho and Rainer Haas
• E-Jahr: 1999
• Jahr: [June 1999]
• Umfang: 9 S.
• Illustrationen: Diagramme
• Fussnoten: Elektronische Reproduktion der Druckausgabe ; Gesehen am 10.12.2021
• Titel Quelle: Enthalten in: British journal of haematology
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1955
• Jahr Quelle: 1999
• Band/Heft Quelle: 105(1999), 3, Seite 786-794
• ISSN Quelle: 1365-2141
• DOI: doi:10.1046/j.1365-2141.1999.01405.x
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CD34
• Sach-SW: haemopoiesis
• Sach-SW: mobilization
• Sach-SW: PBPC
• Sach-SW: steady-state
• K10plus-PPN: 1780955626

Abstract

Peripheral blood progenitor cells (PBPC) can be mobilized using chemotherapy and granulocyte colony-stimulating factor (G-CSF). We and others previously reported a correlation of steady-state PBPC counts and the PBPC yield during mobilization in a small group of patients. Here we present data on 100 patients (patients: 25 non-Hodgkin's lymphoma (NHL), five Hodgkin's disease, 35 multiple myeloma (MM), 35 solid tumour) which enabled a detailed analysis of determinants of steady-state PBPC levels and of mobilization efficiency in patient subgroups. Previous irradiation (P = 0.0034) or previous chemotherapy in patients with haematological malignancies (P = 0.0062) led to a depletion of steady-state PB CD34+ cells. A correlation analysis showed steady-state PB CD34+ cells (all patients: r = 0.52, P < 0.0001; NHL patients, r = 0.69, P = 0.0003; MM patients: r = 0.66, P = 0.0001) and PB colony-forming cells can reliably assess the CD34+ cell yield in mobilized PB. In patients with solid tumour a similar trend was observed in mobilization after the first chemotherapy cycle (r = 0.51, P = 0.05) but not if mobilization occurred after the second or further cycle of a sequential dose-intensified G-CSF-supported chemotherapy regimen, when premobilization CD34+ counts were 18-fold elevated (P = 0.004). When the patients with MM (r = 0.63, P = 0.0008) or with NHL (r = 0.65, P = 0.006) were analysed separately, a highly significant correlation of the steady-state PB CD34+ cell count to the mean leukapheresis CD34+ cell yield was found, whereas no correlation was observed for patients with a solid tumour. For patients with haematological malignancies estimates could be calculated which, at a specific steady-state PB CD34+ cell count, could predict with a 95% probability a defined minimum progenitor cell yield. These results enable recognition of patients who mobilize PBPC poorly and may assist selection of patients for novel mobilization regimens.